Document is current

Article History

Received: 4 April 2025

Accepted: 30 October 2025

First Online: 4 December 2025

Declarations

:

: Alexis Ogdie has received consultancy fees for AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer Inc, Takeda, TREG, and UCB, and research grants for AbbVie, Amgen, Bristol Myers Squibb, Forward/National Databank for Rheumatic Diseases, Janssen, NIH/NIAMS, Novartis, Pfizer Inc, and Rheumatology Research Foundation. Nicole Middaugh is an employee of CorEvitas, LLC (CorEvitas has been supported through contracted subscriptions in the past 2 years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and UCB). Taylor Blachley is an employee of CorEvitas, LLC (CorEvitas has been supported through contracted subscriptions in the past 2 years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and UCB). Tran Bourgeois was an employee of CorEvitas, LLC, at the time of the study (CorEvitas has been supported through contracted subscriptions in the past 2 years by AbbVie, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Genentech, GSK, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and UCB), and is now an employee of the Children’s Hospital of Philadelphia, PA, USA. You-Li Ling is an employee and stockholder of Pfizer Inc. Rajiv Mundayat, Princeton, NJ, USA, is a stockholder of Pfizer Inc and was an employee of Pfizer Inc at the time of the study. Lara Fallon is an employee and stockholder of Pfizer Inc. Karim R. Masri is a stockholder of Pfizer Inc and was an employee of Pfizer Inc at the time of the study, and is now an employee of Candid Therapeutics. Philip J. Mease has been advisor or review panel member for Genascence–Safety Monitoring Board, has received consultancy fees from AbbVie, Acelyrin, Aclaris, Alumis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Lilly, Inmagene, Janssen, MoonLake, Novartis, Pfizer Inc, Takeda, UCB, and Ventyx, has been an officer and board member for Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), OMERACT, and SPARTAN, and has received grant/research support from Amgen, Acelyrin, Bristol Myers Squibb, Lilly, Janssen, Novartis, Pfizer Inc, and UCB.

: The study was performed in accordance with Good Pharmacoepidemiology Practice. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), WCG IRB (no. 120160070). All registry participants provided informed consent and authorization prior to participation. CorEvitas PsA/SpA Registry data used in this analysis were provided in an anonymized structured format and did not contain any patient personal information. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.